Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Lonvoguran ziclumeran
Other

Lonvoguran ziclumeran

Tracked across 1 events · 6 articles · First seen Jun 01, 2026 · Last active Jun 01, 2026

Sentiment
75
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 75
Tech
Intellia to Present lonvo-z Phase 3 Data
Coya Therapeutics announced that data from its global Phase 3 HAELO clinical trial of Lonvoguran ziclumeran, a CRISPR-based gene editing therapy for hereditary angioedema (HAE), will be presented at the European Academy of Allergy and…
Impact: Lonvoguran ziclumeran is the CRISPR-based gene editing therapy being developed by Coya Therapeutics for hereditary angioedema. Positive Phase 3 data could establish it as a groundbreaking one-time treatment.
Jun 01, 2026 · 6 articles
Key Actions (4)
70 United States — Food and Drug Administration granted designations Lonvoguran ziclumeranIntellia to Present...
60 United Kingdom — Medicines and Healthcare products Regulatory Agency granted Innovation Passport Lonvoguran ziclumeranIntellia to Present...
60 European Union — European Medicines Agency granted PRIME Designation Lonvoguran ziclumeranIntellia to Present...
60 International — European Commission granted Orphan Drug Designation Lonvoguran ziclumeranIntellia to Present...
NEWSDESK
Track Lonvoguran ziclumeran live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.